DYAI
Dyadic International, Inc.
NASDAQ · USHealthcareBiotechnology
$1.21-3.97%
Price as of Jul 20, 2026
DYAI financials
Dyadic International, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.2M | $3.5M | $2.9M | $2.9M |
| Cost of revenue | $2.3M | $1.2M | $2.0M | $2.1M |
| Gross profit | -$1.1M | $2.3M | $923.0K | $807.1K |
| Operating expenses | $6.1M | $8.2M | $9.2M | $11.0M |
| Operating income | -$7.1M | -$5.9M | -$8.2M | -$10.2M |
| Net income | -$7.4M | -$5.8M | -$6.8M | -$9.7M |
| EBITDA | -$6.9M | -$5.4M | -$8.2M | -$10.1M |
| Basic EPS | $-0.23 | $-0.20 | $-0.24 | $-0.34 |
| Diluted EPS | $-0.23 | $-0.20 | $-0.24 | $-0.34 |
| Balance sheet | ||||
| Cash & equivalents | $4.6M | $6.5M | $6.5M | $5.8M |
| Total assets | $9.9M | $9.9M | $8.2M | $13.7M |
| Total liabilities | $8.7M | $7.5M | $2.3M | $2.6M |
| Stockholders’ equity | $1.2M | $2.5M | $5.9M | $11.1M |
| Total debt | $5.1M | $5.1M | $136.9K | $0.00 |
| Net debt | $438.3K | -$1.4M | -$6.4M | -$5.8M |
| Cash flow | ||||
| Operating cash flow | -$5.7M | -$4.0M | -$6.7M | -$8.1M |
| Capital expenditure | $0.00 | -$4.00 | $0.00 | $0.00 |
| Free cash flow | -$5.7M | -$4.0M | -$6.7M | -$8.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |